FireTail Names Timo Rüppell as Vice President of Product
FireTail Inc., a disruptor in API security, today announced the appointment of Timo Rüppell to the executive leadership team as Vice President of Product. In conjunction with bringing Rüppell on board, FireTail also opened a new company office in Helsinki, Finland. Historically a strong cybersecurity research center, FireTail looks to expand the company’s talent pool based out of Helsinki and the Baltic States.
Rüppell brings to FireTail a wealth of experience in technology development and team leadership for early stage companies. He will work closely with co-founder and CTO Riley Priddle to define and navigate the development of FireTail’s API security platform. Previously, Rüppell served as CTO at Mapita Ltd. where he was focused on product design, including security, privacy, and compliance management. Earlier in his career, Rüppell leveraged his PhD in theoretical particle physics as a researcher for Helsinki Institute of Physics.
“FireTail is thrilled to welcome Timo to our growing team. With his background and expertise, I am confident Timo will make a lasting impact on the direction of FireTail’s products, as well as the API security market,” said Jeremy Snyder, FireTail co-founder and CEO. “It’s an exciting time for our company as we expand our presence globally, and plant roots in new cities. We look forward to all the collaboration and innovation that will take place at our new office in Helsinki.”
“After another year of watching significant breaches and security incidents at major enterprises play out in the news, the need for a new approach to solving the security threats tied to APIs has never been more clear. I look forward to working with the FireTail team to further their mission of offering simple yet effective API security that makes a positive impact and makes the internet a safer place for everyone,” added Rüppell.
FireTail will be at CloudNativeSecurityCon on Feb. 1-2, 2023 in Seattle, Washington. Visit the team in the Startup Zone to learn more about FireTail’s unique approach to solving API security threats.
The company is actively looking for startup-minded individuals with a passion for application security and cloud technologies to join the team. If you are based in Helsinki and are looking for a new opportunity, learn more about FireTail’s open roles and company culture at firetail.io/careers.
About FireTail
FireTail’s API security platform protects programmable interfaces with inline API call inspection and blocking, API security posture management, centralized API audit, and detection and response capabilities. The cloud-based solution helps organizations scale their API landscape and reduce the attack surface. FireTail makes API security as simple as import, setup, done.
FireTail is headquartered in Northern Virginia, with additional offices in Dublin, Ireland and Helsinki, Finland. To learn more about FireTail’s API security solution visit us at https://firetail.io or follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005251/en/
Contact information
Tori Odom
LaunchTech Communications
+1-443-752-5466
todom@golaunchtech.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom